A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer

NCT01849874

Last updated date
Study Location
University of Arizona Cancer Center
Phoenix, Arizona, 85004, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Low-grade Serous Ovarian Cancer, Low-grade Serous Fallopian Tube Cancer, Low-grade Serous Peritoneal Cancer
Sex
Female
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Diagnosis of LGS carcinoma of the ovary, fallopian tube or primary peritoneum (invasive micropapillary serous carcinoma or invasive grade 1 serous carcinoma), confirmed histologically and verified by central pathology review.

- Recurrent or persistent measurable disease that has progressed (defined as radiological and/or clinical progression; an increase in cancer antigen [CA]-125 alone is not sufficient) on or after last therapy (i.e., chemotherapy, hormonal therapy, surgery) and is not amenable to potentially curative intent surgery, as determined by the patient's treating physician.

- Must have received at least 1 prior platinum-based chemotherapy regimen but have received no more than 3 lines of prior chemotherapy regimens, with no limit to the number of lines of prior hormonal therapy. Front-line therapy may include neoadjuvant and adjuvant therapy and will be counted as 1 prior systemic regimen. Biological therapy (e.g. bevacizumab) administered as a single agent is considered a prior systemic regimen and not a prior chemotherapy regimen. Maintenance therapy is not considered its own regimen but should be included with the regimen that it follows.

- Available archival tumor sample (excisional or core biopsy) for confirmation of LGS carcinoma diagnosis. If adequate archival tumor sample is not available, willingness to consent to tissue biopsy.

- Suitable for treatment with at least one of the physician's choice chemotherapy options (liposomal doxorubicin, paclitaxel or topotecan) as determined by the Investigator.

- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.

- Additional criteria exist.

Key

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- History or current evidence of retinal vein occlusion (RVO) or current risk factors
for RVO (e.g., uncontrolled glaucoma or ocular hypertension, history of hyperviscosity
or hypercoagulability syndromes).


- Prior therapy with a MEK or BRAF inhibitor.


- History of Gilbert's syndrome.


- Impaired cardiovascular function or clinically significant cardiovascular diseases.


- Uncontrolled or symptomatic brain metastases that are not stable or require steroids,
are potentially life-threatening or have required radiation within 28 days prior to
first dose of study treatment.


- Concomitant malignancies or previous malignancies with less than a 5-year disease-free
interval at the time of first dose of study treatment; patients with adequately
resected basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix
or ductal carcinoma in situ may be enrolled irrespective of the time of diagnosis.


- Known positive serology for the human immunodeficiency virus (HIV), active hepatitis B
and/or active hepatitis C.


- Prior randomization into this clinical study.


- Additional criteria exist.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Low-grade Serous Ovarian Cancer, Low-grade Serous Fallopian Tube Cancer, Low-grade Serous Peritoneal CancerA Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer
NCT01849874
  1. Phoenix, Arizona
  2. Phoenix, Arizona
  3. Scottsdale, Arizona
  4. Irvine, California
  5. Los Angeles, California
  6. Los Angeles, California
  7. Los Angeles, California
  8. Los Angeles, California
  9. Los Angeles, California
  10. Los Angeles, California
  11. Los Angeles, California
  12. Los Angeles, California
  13. Los Angeles, California
  14. Orange, California
  15. Orange, California
  16. Santa Monica, California
  17. Valencia, California
  18. Valencia, California
  19. Westlake Village, California
  20. Aurora, Colorado
  21. Aurora, Colorado
  22. Aurora, Colorado
  23. New Haven, Connecticut
  24. Maitland, Florida
  25. Orlando, Florida
  26. Orlando, Florida
  27. Orlando, Florida
  28. Tampa, Florida
  29. Wellington, Florida
  30. West Palm Beach, Florida
  31. Augusta, Georgia
  32. Augusta, Georgia
  33. Augusta, Georgia
  34. Chicago, Illinois
  35. Westmont, Illinois
  36. Indianapolis, Indiana
  37. Indianapolis, Indiana
  38. Indianapolis, Indiana
  39. Indianapolis, Indiana
  40. Iowa City, Iowa
  41. Baltimore, Maryland
  42. Billerica, Massachusetts
  43. Billerica, Massachusetts
  44. Cambridge, Massachusetts
  45. Detroit, Michigan
  46. Detroit, Michigan
  47. Farmington Hills, Michigan
  48. Saint Louis, Missouri
  49. Saint Louis, Missouri
  50. Saint Louis, Missouri
  51. Saint Louis, Missouri
  52. Billings, Montana
  53. Albuquerque, New Mexico
  54. Albuquerque, New Mexico
  55. Bronx, New York
  56. Bronx, New York
  57. Bronx, New York
  58. Bronx, New York
  59. Harrison, New York
  60. New York, New York
  61. Cincinnati, Ohio
  62. Cleveland, Ohio
  63. Cleveland, Ohio
  64. Cleveland, Ohio
  65. Cleveland, Ohio
  66. Columbus, Ohio
  67. Columbus, Ohio
  68. Columbus, Ohio
  69. Hilliard, Ohio
  70. Mayfield Heights, Ohio
  71. Mayfield Heights, Ohio
  72. West Chester, Ohio
  73. Oklahoma City, Oklahoma
  74. Oklahoma City, Oklahoma
  75. Philadelphia, Pennsylvania
  76. Philadelphia, Pennsylvania
  77. Pittsburgh, Pennsylvania
  78. Pittsburgh, Pennsylvania
  79. Dallas, Texas
  80. Dallas, Texas
  81. Dallas, Texas
  82. Dallas, Texas
  83. Houston, Texas
  84. Charlottesville, Virginia
  85. Wahroonga, New South Wales
  86. Wahroonga, New South Wales
  87. Westmead, New South Wales
  88. South Brisbane, Queensland
  89. Adelaide, South Australia
  90. Adelaide, South Australia
  91. Adelaide, South Australia
  92. Norwood, South Australia
  93. Toorak Gardens, South Australia
  94. St Albans, Victoria
  95. Nedlands, Western Australia
  96. Innsbruck, Tirol
  97. Libramont, Luxembourg
  98. Libramont, Luxembourg
  99. Leuven, Vlaams-brabant
  100. Brussels,
  101. Gent,
  102. Gent,
  103. Liege,
  104. Namur,
  105. Wilrijk,
  106. Calgary, Alberta
  107. Calgary, Alberta
  108. Vancouver, British Columbia
  109. Winnipeg, Manitoba
  110. Hamilton, Ontario
  111. Toronto, Ontario
  112. Montreal, Quebec
  113. Montreal, Quebec
  114. Shanghai,
  115. Hradec Kralove,
  116. Olomouc,
  117. Ostrava - Poruba,
  118. Ostrava - Poruba,
  119. Ostrava-Poruba,
  120. Prague 2,
  121. Prague,
  122. Aalborg, North Jutland
  123. Aalborg, North Jutland
  124. Kobenhavn o,
  125. Kobenhavn o,
  126. København Ø,
  127. København Ø,
  128. Tampere,
  129. Besancon,
  130. Lille,
  131. Lille,
  132. LYON Cedex 08,
  133. Lyon,
  134. Marseille Cedex 09,
  135. Marseille,
  136. Montferrier S/lez,
  137. Montpellier Cedex 5,
  138. Montpellier CEDEX 5,
  139. NANTES Cedex 2,
  140. Nantes,
  141. Nantes,
  142. Paris Cedex 15,
  143. Paris,
  144. Plerin,
  145. Saint-Herblain Cedex,
  146. Villejuif Cedex,
  147. Tuebingen, Baden-wuerttemberg
  148. Ulm, Baden-wurttemberg
  149. Munich, Bavaria
  150. Kassel, Hessen
  151. Essen, North Rhine-westphalia
  152. Bonn, North-rhine Westphalia
  153. Dresden, Saxony
  154. Kiel, Schleswig-holstein
  155. Berlin,
  156. Freiburg,
  157. Greifswald,
  158. Heidelberg,
  159. Gyor, Gyor-moson-sopron
  160. Gyor, Gyor-moson-sopron
  161. Gyor, Gyor-moson-sopron
  162. Budapest,
  163. Budapest,
  164. Budapest,
  165. Budapest,
  166. Budapest,
  167. Budapest,
  168. Budapest,
  169. Dublin, Dublin 8
  170. Dublin,
  171. Rozzano, Milano
  172. Aviano, Pordenone
  173. Faenza, Ravenna
  174. Faenza, Ravenna
  175. Lugo, Ravenna
  176. Roma, RM
  177. Roma, Rome
  178. Roma, Rome
  179. Bologna,
  180. Bologna,
  181. Brescia,
  182. Brescia,
  183. Catania,
  184. Milano,
  185. Milano,
  186. Milano,
  187. Napoli,
  188. Napoli,
  189. Napoli,
  190. Napoli,
  191. Ravenna,
  192. Ravenna,
  193. Roma,
  194. Roma,
  195. Amsterdam, Noord-holland
  196. Groningen,
  197. Maastricht,
  198. Oslo,
  199. Oslo,
  200. Oslo,
  201. Warsaw,
  202. L'Hospitalet de Llobregat, Barcelona
  203. Córdoba, Castilla LA Mancha
  204. Anoeta, Guipuzcoa
  205. San Sebastian, Guipuzcoa
  206. Barcelona,
  207. Barcelona,
  208. Barcelona,
  209. Barcelona,
  210. Cordoba,
  211. Cordoba,
  212. Cordoba,
  213. Cordoba,
  214. L'Hospitalet de Llobregat,
  215. Madrid,
  216. Palma de Mallorca,
  217. Sevilla,
  218. Toledo,
  219. Valencia,
  220. Valencia,
  221. Stockholm,
  222. Uppsala,
  223. London, England
  224. Nottingham, Nottinghamshire
  225. Nottingham, Nottinghamshire
  226. Ashtead, Surrey
  227. Epsom, Surrey
  228. Sutton, Surrey
  229. North Cheam, Sutton
  230. Birmingham, WEST Midlands
  231. London,
  232. London,
  233. London,
  234. Manchester,
Female
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer
Official Title  ICMJE The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum
Brief Summary The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer) is a Phase 3 study during which patients with recurrent or persistent low-grade serous (LGS) carcinomas of the ovary, fallopian tube or primary peritoneum will receive either investigational study drug MEK162 or a chemotherapy chosen by the physician (liposomal doxorubicin, paclitaxel or topotecan). Patients will be followed to compare the effectiveness of the study drug to that of the selected chemotherapies. Patients may be eligible to crossover from physician's choice chemotherapy to MEK162 if they meet certain inclusion criteria including centrally confirmed disease progression. Approximately 360 patients from North America, Europe and Australia will be enrolled in this study.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Low-grade Serous Ovarian Cancer
  • Low-grade Serous Fallopian Tube Cancer
  • Low-grade Serous Peritoneal Cancer
Intervention  ICMJE
  • Drug: MEK162, MEK inhibitor; oral
    multiple dose, single schedule
  • Drug: Physician's choice chemotherapy

    Patients will receive one of the following chemotherapies as determined by the physician:

    • Liposomal doxorubicin, anthracycline antibiotic; intravenous (multiple dose, single schedule)
    • Paclitaxel, mitotic inhibitor; intravenous (multiple dose, single schedule)
    • Topotecan, topoisomerase 1 inhibitor; intravenous (multiple dose, single schedule)
Study Arms  ICMJE
  • Experimental: MEK162
    Intervention: Drug: MEK162, MEK inhibitor; oral
  • Active Comparator: Physician's choice chemotherapy
    Intervention: Drug: Physician's choice chemotherapy
Publications * Monk BJ, Grisham RN, Banerjee S, Kalbacher E, Mirza MR, Romero I, Vuylsteke P, Coleman RL, Hilpert F, Oza AM, Westermann A, Oehler MK, Pignata S, Aghajanian C, Colombo N, Drill E, Cibula D, Moore KN, Christy-Bittel J, Del Campo JM, Berger R, Marth C, Sehouli J, O'Malley DM, Churruca C, Boyd AP, Kristensen G, Clamp A, Ray-Coquard I, Vergote I. MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum. J Clin Oncol. 2020 Nov 10;38(32):3753-3762. doi: 10.1200/JCO.20.01164. Epub 2020 Aug 21.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: March 3, 2021)
341
Original Estimated Enrollment  ICMJE
 (submitted: May 7, 2013)
300
Estimated Study Completion Date  ICMJE June 30, 2021
Actual Primary Completion Date December 1, 2015   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Key Inclusion Criteria:

  • Diagnosis of LGS carcinoma of the ovary, fallopian tube or primary peritoneum (invasive micropapillary serous carcinoma or invasive grade 1 serous carcinoma), confirmed histologically and verified by central pathology review.
  • Recurrent or persistent measurable disease that has progressed (defined as radiological and/or clinical progression; an increase in cancer antigen [CA]-125 alone is not sufficient) on or after last therapy (i.e., chemotherapy, hormonal therapy, surgery) and is not amenable to potentially curative intent surgery, as determined by the patient's treating physician.
  • Must have received at least 1 prior platinum-based chemotherapy regimen but have received no more than 3 lines of prior chemotherapy regimens, with no limit to the number of lines of prior hormonal therapy. Front-line therapy may include neoadjuvant and adjuvant therapy and will be counted as 1 prior systemic regimen. Biological therapy (e.g. bevacizumab) administered as a single agent is considered a prior systemic regimen and not a prior chemotherapy regimen. Maintenance therapy is not considered its own regimen but should be included with the regimen that it follows.
  • Available archival tumor sample (excisional or core biopsy) for confirmation of LGS carcinoma diagnosis. If adequate archival tumor sample is not available, willingness to consent to tissue biopsy.
  • Suitable for treatment with at least one of the physician's choice chemotherapy options (liposomal doxorubicin, paclitaxel or topotecan) as determined by the Investigator.
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.
  • Additional criteria exist.

Key Exclusion Criteria:

  • History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO (e.g., uncontrolled glaucoma or ocular hypertension, history of hyperviscosity or hypercoagulability syndromes).
  • Prior therapy with a MEK or BRAF inhibitor.
  • History of Gilbert's syndrome.
  • Impaired cardiovascular function or clinically significant cardiovascular diseases.
  • Uncontrolled or symptomatic brain metastases that are not stable or require steroids, are potentially life-threatening or have required radiation within 28 days prior to first dose of study treatment.
  • Concomitant malignancies or previous malignancies with less than a 5-year disease-free interval at the time of first dose of study treatment; patients with adequately resected basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix or ductal carcinoma in situ may be enrolled irrespective of the time of diagnosis.
  • Known positive serology for the human immunodeficiency virus (HIV), active hepatitis B and/or active hepatitis C.
  • Prior randomization into this clinical study.
  • Additional criteria exist.
Sex/Gender  ICMJE
Sexes Eligible for Study:Female
Gender Based Eligibility:Yes
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Australia,   Austria,   Belgium,   Canada,   China,   Czechia,   Denmark,   Finland,   France,   Germany,   Hungary,   Ireland,   Italy,   Netherlands,   Norway,   Poland,   Spain,   Sweden,   United Kingdom,   United States
Removed Location Countries Czech Republic,   Luxembourg
 
Administrative Information
NCT Number  ICMJE NCT01849874
Other Study ID Numbers  ICMJE ARRAY-162-311
C4211003 ( Other Identifier: Alias Study Number )
2013-000277-72 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD:Yes
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
URL:https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d…
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date March 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP